BiotechTube

Apitegromab + Placebo

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Facioscapulohumeral Muscular Dystrophy

Conditions

Facioscapulohumeral Muscular Dystrophy, FSHD

Trial Timeline

Aug 1, 2026 → Dec 1, 2028

NCT ID
NCT07435129

About Apitegromab + Placebo

Apitegromab + Placebo is a phase 2 stage product being developed by Scholar Rock Holding for Facioscapulohumeral Muscular Dystrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07435129. Target conditions include Facioscapulohumeral Muscular Dystrophy, FSHD.

What happened to similar drugs?

0 of 2 similar drugs in Facioscapulohumeral Muscular Dystrophy were approved

Approved (0) Terminated (1) Active (1)
🔄AOC-1020 + PlaceboAvidity BiosciencesPhase 3
❌Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07435129Phase 2Recruiting
NCT05156320Phase 3Completed

Competing Products

12 competing products in Facioscapulohumeral Muscular Dystrophy

See all competitors
ProductCompanyStageHype Score
ACE-083 + ACE-083 or placeboMerckPhase 2
27
ACE-083MerckPhase 2
27
Placebo + RO7204239RochePhase 2
39
AOC-1020 + PlaceboAvidity BiosciencesPhase 3
44
Losmapimod oral tablet + Placebo oral tabletFulcrum TherapeuticsPhase 2
25
Losmapimod + Placebo oral tabletFulcrum TherapeuticsPhase 3
22
LosmapimodFulcrum TherapeuticsPhase 2
17
LosmapimodFulcrum TherapeuticsPhase 2
17
ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22
Placebo + ATYR1940aTyr PharmaPhase 1/2
22
ATYR1940aTyr PharmaPhase 1/2
22